Longport Leads UK Government Supported Project to Develop High Performance Ultrasound System

  
    
  
  
    
      Longport, Inc. (OTC PK: LPTI), a medical technology specialist in 
      high-frequency high resolution ultrasound imaging, today announced that 
      its UK subsidiary, Longport International, is participating in a $2 
      million project to develop a high resolution phased array ultrasound 
      imaging system. This project is partly supported by a grant from the UK’s 
      Department of Trade & Industry. The system under development will be 
      capable of imaging at center frequencies greater than 25 MHz as well as 
      at lower frequencies and is expected to exceed the imaging resolution of 
      all current commercial multi-element ultrasound systems.
    
    
      The project, which is led by Longport International, involves the 
      University of Manchester, Phoenix Inspection, and Newbury Electronics, 
      all from the UK. Importantly, the system under development will combine 
      very high performance with affordability through the utilization of 
      novel transducer and system designs and the development of specialist 
      integrated circuits. Initial applications for this system are expected 
      to be cancer imaging, including the mapping of skin cancers, wound 
      assessment and prevention and superficial musculoskeletal imaging as 
      well as specialist engineering inspections.
    
    
      Welcoming the new partnership, the UK’s 
      Science and Innovation Minister, Lord Sainsbury, said, “This 
      initiative provides a real opportunity to harness the world class 
      expertise that we possess in the UK and direct it towards the task of 
      wealth creation. By providing a focus for collaboration and delivery, 
      this partnership should establish British industry as the world leader 
      in this area and be an attractive proposition for investors.”
    
    
      Paul Wilson, Managing Director of Longport International, said, “This 
      project will build on expertise developed by Longport and the University 
      of Manchester in high resolution ultrasound imaging and is seen as a 
      logical evolution of Longport’s established 
      medical imaging technology. The development is expected to bring the 
      benefits of faster imaging as well as a broader range of image 
      enhancement and processing techniques, including Doppler imaging, to 
      Longport’s current customer groupings as well 
      as expanding the markets that Longport can address.”
    
    
      About Longport, Inc.
    
    
      Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology 
      company that specializes in high resolution ultrasound imaging. After 
      several years and a multi-million dollar investment in the technology, 
      Longport has secured patents, copyrights and FDA permission to market. 
      The Company’s technology has been used to 
      engineer a unique high resolution ultrasound imaging system. For further 
      information please contact Longport, Inc. at 1-800-289-6863 or visit our 
      website at www.longportinc.com.
    
    
      Forward-looking Information and the Private Securities Litigation 
      Reform Act of 1995
    
    
      Certain statements in this press release, including statements 
      concerning product development milestones and anticipated events, are “forward-looking 
      statements” within the Private Litigation 
      Reform Act of 1995. Forward Looking Statements are based on the 
      opinions and estimates of management at the time the statements are made 
      and are subject to certain risks and uncertainties that could cause 
      actual results to differ materially from those anticipated in the 
      forward-looking statements. The words “believe,” 
      “expect,” “intend,” 
      “anticipate,” 
      variations of such words, and similar expressions identify 
      forward-looking statements, but their absence does not mean that the 
      statement is not forward-looking. These statements are not 
      guarantees of future performance and are subject to certain risks, 
      uncertainties and assumptions that are difficult to predict. Factors 
      that could affect Longport’s actual results 
      include, among others, uncertainties as to the Company’s 
      ability to manage potential problems, delays or anticipated expenses, 
      including problems, delays or expenses involving manufacturing. Readers 
      are cautioned not to place undue reliance upon these forward-looking 
      statements that speak only to the date of this release. Reference 
      is made to Longport’s 2004 annual report on 
      Form 10-K filed with the Securities and Exchange Commission for a more 
      definitive description of such factors. Longport, Inc. undertakes 
      no obligation to update publicly any forward-looking statements to 
      reflect new information, events or circumstances after the date of this 
      release or to reflect the occurrence of unanticipated events.
    
  
Longport, Inc. (OTC PK: LPTI), a medical technology specialist in
high-frequency high resolution ultrasound imaging, today announced
that its UK subsidiary, Longport International, is participating in a
$2 million project to develop a high resolution phased array
ultrasound imaging system. This project is partly supported by a grant
from the UK's Department of Trade & Industry. The system under
development will be capable of imaging at center frequencies greater
than 25 MHz as well as at lower frequencies and is expected to exceed
the imaging resolution of all current commercial multi-element
ultrasound systems.

   The project, which is led by Longport International, involves the
University of Manchester, Phoenix Inspection, and Newbury Electronics,
all from the UK. Importantly, the system under development will
combine very high performance with affordability through the
utilization of novel transducer and system designs and the development
of specialist integrated circuits. Initial applications for this
system are expected to be cancer imaging, including the mapping of
skin cancers, wound assessment and prevention and superficial
musculoskeletal imaging as well as specialist engineering inspections.

   Welcoming the new partnership, the UK's Science and Innovation
Minister, Lord Sainsbury, said, "This initiative provides a real
opportunity to harness the world class expertise that we possess in
the UK and direct it towards the task of wealth creation. By providing
a focus for collaboration and delivery, this partnership should
establish British industry as the world leader in this area and be an
attractive proposition for investors."

   Paul Wilson, Managing Director of Longport International, said,
"This project will build on expertise developed by Longport and the
University of Manchester in high resolution ultrasound imaging and is
seen as a logical evolution of Longport's established medical imaging
technology. The development is expected to bring the benefits of
faster imaging as well as a broader range of image enhancement and
processing techniques, including Doppler imaging, to Longport's
current customer groupings as well as expanding the markets that
Longport can address."

   About Longport, Inc.

   Longport, Inc. of Glen Mills, Pennsylvania, is a medical
technology company that specializes in high resolution ultrasound
imaging. After several years and a multi-million dollar investment in
the technology, Longport has secured patents, copyrights and FDA
permission to market. The Company's technology has been used to
engineer a unique high resolution ultrasound imaging system. For
further information please contact Longport, Inc. at 1-800-289-6863 or
visit our website at www.longportinc.com.

   Forward-looking Information and the Private Securities Litigation
Reform Act of 1995

   Certain statements in this press release, including statements
concerning product development milestones and anticipated events, are
"forward-looking statements" within the Private Litigation Reform Act
of 1995. Forward Looking Statements are based on the opinions and
estimates of management at the time the statements are made and are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those anticipated in the
forward-looking statements. The words "believe," "expect," "intend,"
"anticipate," variations of such words, and similar expressions
identify forward-looking statements, but their absence does not mean
that the statement is not forward-looking. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Factors
that could affect Longport's actual results include, among others,
uncertainties as to the Company's ability to manage potential
problems, delays or anticipated expenses, including problems, delays
or expenses involving manufacturing. Readers are cautioned not to
place undue reliance upon these forward-looking statements that speak
only to the date of this release. Reference is made to Longport's 2004
annual report on Form 10-K filed with the Securities and Exchange
Commission for a more definitive description of such factors.
Longport, Inc. undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date of this release or to reflect the
occurrence of unanticipated events.